2nd Quarter - Report

RARE DISEASE COMPANY COALITION for RARE DISEASE COMPANY COALITION

Firm
Client
Income
—
Expenses
$70,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

HR 1 - Big Beautiful Bill Act

LobbyistCovered position, as disclosed
STACEY FRISK —
YOKO ROSENBAUM —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1 (119th)

Pharmacy PHA

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities

LobbyistCovered position, as disclosed
STACEY FRISK —
YOKO ROSENBAUM —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 946 (119th), H.R. 1414 (119th), H.R. 1262 (119th)

Science/Technology SCI

Executive Order 14297 - Impact of EO on Rare Disease Innovation Rare Disease Policy

LobbyistCovered position, as disclosed
STACEY FRISK —
YOKO ROSENBAUM —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Sec. 232 Pharmaceutical Tariffs

LobbyistCovered position, as disclosed
YOKO ROSENBAUM —

Contacted: U.S. Trade Representative (USTR)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.